Treating advanced radioresistant differentiated thyroid cancer

被引：6
作者：
Bible, Keith C. [1 ]
机构：
[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 09期
关键词：
PHASE-II TRIAL; SORAFENIB;
D O I：
10.1016/S1470-2045(12)70342-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：854 / 855
页数：3
相关论文
共 11 条
  • [1] Al-Eid HS., CANC INCIDENCE REPOR
  • [2] American Cancer Society, 2012, Cancer Facts and Figures 2012
  • [3] Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
    Bible, Keith C.
    Suman, Vera J.
    Molina, Julian R.
    Smallridge, Robert C.
    Maples, William J.
    Menefee, Michael E.
    Rubin, Joseph
    Sideras, Kostandinos
    Morris, John C., III
    McIver, Bryan
    Burton, Jill K.
    Webster, Kevin P.
    Bieber, Carolyn
    Traynor, Anne M.
    Flynn, Patrick J.
    Goh, Boon Cher
    Tang, Hui
    Ivy, Susan Percy
    Erlichman, Charles
    [J]. LANCET ONCOLOGY, 2010, 11 (10) : 962 - 972
  • [4] Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
    Carr, Laurie L.
    Mankoff, David A.
    Goulart, Bernardo H.
    Eaton, Keith D.
    Capell, Peter T.
    Kell, Elizabeth M.
    Bauman, Julie E.
    Martins, Renato G.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (21) : 5260 - 5268
  • [5] Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
    Cohen, Ezra E. W.
    Rosen, Lee S.
    Vokes, Everett E.
    Kies, Merrill S.
    Forastiere, Arlene A.
    Worden, Francis P.
    Kane, Madeleine A.
    Sherman, Eric
    Kim, Sinil
    Bycott, Paul
    Tortorici, Michael
    Shalinsky, David R.
    Liau, Katherine F.
    Cohen, Roger B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4708 - 4713
  • [6] Phase II trial of sorafenib in advanced thyroid cancer
    Gupta-Abramson, Vandana
    Troxel, Andrea B.
    Nellore, Anoma
    Puttaswamy, Kanchan
    Redlinger, Maryann
    Ransone, Kathy
    Mandel, Susan J.
    Flaherty, Keith T.
    Loevner, Laurie A.
    O'Dwyer, Peter J.
    Brose, Marcia S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4714 - 4719
  • [7] Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
    Kloos, Richard T.
    Ringel, Matthew D.
    Knopp, Michael V.
    Hall, Nathan C.
    King, Mark
    Stevens, Robert
    Liang, Jiachao
    Wakely, Paul E., Jr.
    Vasko, Vasyl V.
    Saji, Motoyasu
    Rittenberry, Jennifer
    Wei, Lai
    Arbogast, Daria
    Collamore, Minden
    Wright, John J.
    Grever, Michael
    Shah, Manisha H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1675 - 1684
  • [8] Leboulleux S, 2012, LANCET ONCOL
  • [9] Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
    Schutz, Fabio A. B.
    Je, Youjin
    Richards, Christopher J.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 871 - 877
  • [10] Cancers with increasing incidence trends in the United States: 1999 through 2008
    Simard, Edgar P.
    Ward, Elizabeth M.
    Siegel, Rebecca
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2012, 62 (02) : 118 - 128
12